CRS-207

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameCRS-207
Drug Alias NameListeria monocytogenes-expressing mesothelinCRS-207ANZ-207
ClassificationVaccines > Development/production technology > Live attenuated vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsPancreatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesJohns Hopkins Bloomberg School Of Public HealthCerus CorpChugai Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesAduro Biotech Inc
Active IndicationsPancreatic Neoplasms
Inactive IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsStomach Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A